Glenmark Says Phase III Trials of Diabetes Drug Will Start by Year-end

by Rajashri on  June 24, 2009 at 6:50 PM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

 Glenmark Says Phase III Trials of Diabetes Drug Will Start by Year-end
Glenmark Pharmaceuticals Ltd has announced that it is all set to begin final stage global clinical trials for its experimental new molecule Melogliptin by the end of the year. The latter is a new treatment for diabetes.

Glenmark said the drug had successfully completed phase IIb, or mid-stage, clinical trials. The results showed that it was able to improve glycemic control and also had a neutral effect on body weight. The 12-week trial involved 494 patients and all of them had reduced instances of low blood sugar level.

The company added in a statement that it is still looking to outlicense the molecule.



Source: Medindia
RAS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Diabetic Retinopathy Drug Toxicity Diabetes Diabetic Diet Diabetes - Essentials Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices Diabetes and Exercise Signature Drug Toxicity Stress Relief Through Alternative Medicine 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive